DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
WST logo

West Pharmaceutical Services, Inc. Stock Price

NYSE:WST Community·US$25.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 32 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

WST Share Price Performance

US$362.31
110.09 (43.65%)
​
US$403.93
Fair Value
US$362.31
110.09 (43.65%)
10.3% undervalued intrinsic discount
US$403.93
Fair Value
Price US$362.31
AnalystConsensusTarget US$403.93
Tue, 28 Jul 26
Fair ValueUS$403.93
Share Pricen/a

WST Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$403.93 10.3% undervalued intrinsic discount

Analysts Raise Target for West Pharmaceutical Services Amid Strong Outlook and Upgraded Guidance

0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
WST logo
West Pharmaceutical Services
10.3% undervalued intrinsic discount

Analysts Raise Target for West Pharmaceutical Services Amid Strong Outlook and Upgraded Guidance

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 28 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
WST logo

WST: High Value Injectable Demand And GLP 1 Exposure Will Drive Future Returns

Fair Value: US$403.93 10.3% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with proven track record.

0 Risks
2 Rewards
View Full Analysis

West Pharmaceutical Services, Inc. Key Details

US$3.3b

Revenue

US$2.1b

Cost of Revenue

US$1.2b

Gross Profit

US$658.9m

Other Expenses

US$564.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
8.03
36.79%
16.98%
6.8%
View Full Analysis

About WST

Founded
1923
Employees
10800
CEO
Michel Lagarde
WebsiteView website
www.westpharma.com

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Recent WST News & Updates

User avatar
Narrative Update • Jul 28

WST: High Value Injectable Demand And GLP 1 Exposure Will Drive Future Returns

The updated analyst price target for West Pharmaceutical Services has moved higher from $379 to about $404. This reflects analysts’ revised models that incorporate slightly lower revenue growth assumptions, a modest improvement in profit margin expectations, and a somewhat higher future P/E multiple.

Recent updates

No updates

West Pharmaceutical Services, Inc. Competitors

GILD logo

Gilead Sciences

Symbol: NasdaqGS:GILD
Market cap: US$186.1b
PFE logo

Pfizer

Symbol: NYSE:PFE
Market cap: US$157.7b
DHR logo

Danaher

Symbol: NYSE:DHR
Market cap: US$148.9b
VRTX logo

Vertex Pharmaceuticals

Symbol: NasdaqGS:VRTX
Market cap: US$128.8b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide